Novo Holdings A/S’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Novo Holdings A/S’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-13,786	Closed	-$8.38M	–	33
2019 Q2	$8.38M	Sell	13,786 -5,029	-27%	-$3.08M	1.17%	17
2019 Q1	$11.5M	Hold	18,815	–	–	1.7%	13
2018 Q4	$6.87M	Hold	18,815	–	–	0.97%	18
2018 Q3	$12.7M	Buy	18,815 +7,260	+63%	+$5.15M	1.01%	15
2018 Q2	$10.1M	Sell	11,555 -144	-1%	-$165K	1.01%	14
2018 Q1	$14.7M	Hold	11,699	–	–	1.84%	11
2017 Q4	$17.5M	Buy	11,699 +84	+0.7%	+$133K	2.45%	7
2017 Q3	$23.8M	Buy	11,615 +2,309	+25%	+$5.42M	3.1%	10
2017 Q2	$24.4M	Hold	9,306	–	–	2.92%	10
2017 Q1	$27.9M	Hold	9,306	–	–	2.97%	12
2016 Q4	$13.9M	Buy	9,306 +4,839	+108%	+$6.42M	1.32%	15
2016 Q3	$7.87M	Buy	4,467 +248	+6%	+$478K	0.7%	13
2016 Q2	$7.91M	Buy	4,219 +719	+21%	+$1.45M	0.83%	14
2016 Q1	$7.84M	Hold	3,500	–	–	0.86%	10
2015 Q4	$8.42M	Buy	3,500 +31	+0.9%	+$75.6K	0.81%	8
2015 Q3	$8.24M	Buy	+3,469	New	+$9.2M	0.85%	16

Other funds holding NBRV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Novo Holdings A/S's NBRV Position: Q3 2019 in Review

Novo Holdings A/S sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2019, closing a stake of 13,786 shares — an estimated $8.38M sold.

Novo Holdings A/S first reported a position in NBRV in Q3 2015 and held it in 16 quarters. The position peaked at $27.9M in Q1 2017. 44 funds tracked by Wall St. Rank hold NBRV as of Q3 2019.

Novo Holdings A/S reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2019 after selling out during the quarter.
Novo Holdings A/S sold 13,786 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2019, an estimated $8.38M.
Novo Holdings A/S first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2015 and held it in 16 quarters.
Novo Holdings A/S's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $27.9M in Q1 2017.
44 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2019.

Based on Novo Holdings A/S's 13F filing for Q3 2019, filed 14 Nov 2019.